Off-label prescribing in ophthalmology: a retrospective analysis
Frontiers in Pharmacology · 11.06.2026 · 17
DOI: 10.3389/fphar.2026.1837220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.06.2026. Verfasst von Claudio Bucolo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. Die Arbeit nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Off-label practice is often needed in ophthalmology, due to the limited number of drugs approved to treat several ocular diseases and to manage challenging ocular surgeries. The aim was to analyze the off-label drug prescriptions issued from January 2014 to December 2024 at the Department of Ophthalmology of the University Hospital of Catania (Italy). 233 off-label prescriptions, comprising 13 drugs, were delivered to treat 225 patients affected by ocular disorders. Results of the present study showed a raise of off-label prescriptions in 2015 and 2016 mainly due to mitomycin C use in trabeculectomy, representing 34.3% of the total off-label drug prescriptions in the reference period. After a decrease in 2017–2018, there was an increasing trend in the number of off-label issued prescriptions until 2024. The main contributors were anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab, ranibizumab and aflibercept, which represent 25.3%, 9.0% and 4.3% of off-label prescriptions, respectively. Additionally, 5-fluorouracil and dexamethasone were prescribed off-label, each representing 7.3% of the total off-label prescriptions, to mainly handle conjunctival carcinoma and various macular edema, respectively. Alteplase (6.9%), voriconazole (2.1%), verteporfin (1.3%), and foscarnet (0.9%), together with amphotericin B (0.4%), ganciclovir (0.4%), as well as rituximab (0.4%) were off-label prescribed to manage other specific ocular conditions. These results suggest that off-label practice is evolving in the field of ophthalmology. Collaboration among regulatory authorities, clinicians, marketing authorization holders, and patients is essential, in order to develop standardized, evidence-based international guidelines about off-label use, to improve outcome of patients with unmet medical needs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
- Pharmacy Operative Complex Unit, University Hospital "G. Rodolico", Catania, Italy.
- Centre for Research and Consultancy in HTA and Drug Regulatory Affairs (CERD), University of Catania, Catania, Italy.
- HTA Commission, University Hospital of Catania, Catania, Italy.
- Pharmacy Operative Complex Unit, University Hospital "San Marco", Catania, Italy.
- Department of Medicine and Surgery, University of Enna "Kore", Enna, Italy.
Zitieren
APA
Bucolo, C., Gozzo, L., Terranova, L., Badagliacca, M. R., Romano, G. L., Avitabile, A., Russo, A., Lazzara, A., Drago, F., & Conti, F. (2026). Off-label prescribing in ophthalmology: a retrospective analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1837220
Vancouver
Bucolo C, Gozzo L, Terranova L, Badagliacca MR, Romano GL, Avitabile A, et al. Off-label prescribing in ophthalmology: a retrospective analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1837220
BibTeX
@article{Bucolo2026,
author = {Bucolo, Claudio and Gozzo, Lucia and Terranova, Laura and Badagliacca, Maria Rita and Romano, Giovanni Luca and Avitabile, Alessandro and Russo, Andrea and Lazzara, Antonio and Drago, Filippo and Conti, Federica},
title = {Off-label prescribing in ophthalmology: a retrospective analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1837220}
}
EUVIMED